{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:05:44Z","timestamp":1789884344466,"version":"4.0.1"},"reference-count":72,"publisher":"Akademiai Kiado Zrt.","issue":"38","content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,9,20]]},"abstract":"A hypertrophi\u00e1s cardiomyopathia a leggyakoribb struktur\u00e1lis sz\u00edvizombetegs\u00e9g,\n nemzetk\u00f6zi adatok alapj\u00e1n prevalenci\u00e1ja 1\u00a0:\u00a0500-ra tehet\u0151 a feln\u0151tt lakoss\u00e1g\n k\u00f6r\u00e9ben, azonban rendk\u00edv\u00fcl heterog\u00e9n klinikai megjelen\u00e9s \u00e9s v\u00e1ltozatos\n k\u00f3rlefoly\u00e1s jellemzi. A betegek mintegy 10%-\u00e1n\u00e1l ismerik fel a betegs\u00e9get,\n 90%-ukn\u00e1l nem diagnosztiz\u00e1lj\u00e1k a k\u00f3rk\u00e9pet. Az ut\u00f3bbi betegek t\u00f6bbs\u00e9g\u00e9n\u00e9l t\u00fcnetek\n hi\u00e1ny\u00e1ban nem ker\u00fcl sor kivizsg\u00e1l\u00e1sra, a hirtelen sz\u00edvhal\u00e1l h\u00e1tter\u00e9ben azonban\n gyakorta hypertrophi\u00e1s cardiomyopathia \u00e1ll k\u00f3roki t\u00e9nyez\u0151k\u00e9nt. Az elm\u00falt\n \u00e9vekben, \u00e9vtizedekben a javul\u00f3 eszk\u00f6z\u00f6s \u00e9s gy\u00f3gyszeres ter\u00e1pi\u00e1s lehet\u0151s\u00e9geknek\n k\u00f6sz\u00f6nhet\u0151en a hypertrophi\u00e1s cardiomyopathi\u00e1b\u00f3l ad\u00f3d\u00f3 mortalit\u00e1s cs\u00f6kken\u0151\n tendenci\u00e1t mutat. C\u00e9lunk az elm\u00falt \u00e9vekben publik\u00e1lt nemzetk\u00f6zi Ir\u00e1nyelvek\n szellemis\u00e9g\u00e9ben bemutatni a betegs\u00e9g epidemiol\u00f3giai jelent\u0151s\u00e9g\u00e9t, hangs\u00falyozva a\n diagnosztikus \u201e\u00e9bers\u00e9g\u201d \u00e9s a multiparametrikus kivizsg\u00e1l\u00e1s fontoss\u00e1g\u00e1t. A\n cardiomyopathia-szeml\u00e9let kialak\u00edt\u00e1s\u00e1nak hangs\u00falyoz\u00e1s\u00e1val fel szeretn\u00e9nk h\u00edvni a\n figyelmet a klinikai gyan\u00fajelek keres\u00e9s\u00e9re, hogy m\u00e1r az alapell\u00e1t\u00e1sban \u00e9s az\n \u00e1ltal\u00e1nos kardiol\u00f3giai szakrendel\u0151kben is min\u00e9l hamarabb kiemelj\u00e9k a\n hypertrophi\u00e1s cardiomyopathi\u00e1ra gyan\u00fas betegeket, ezzel el\u0151seg\u00edtve a miel\u0151bbi\n diagn\u00f3zist \u00e9s az adekv\u00e1t gy\u00f3gyszeres\/eszk\u00f6z\u00f6s ter\u00e1pia be\u00e1ll\u00edt\u00e1s\u00e1t. Ismertetj\u00fck\n az Eur\u00f3pai Kardiol\u00f3gus T\u00e1rsas\u00e1g 2023-as Cardiomyopathia Ir\u00e1nyelve \u00e1ltal javasolt\n diagnosztikus \u00fat, valamint a multiparametrikus, multimod\u00e1lis kivizsg\u00e1l\u00e1s\n alapvet\u0151 elemeit, illetve a felismerhet\u0151 klinikai gyan\u00fajeleket. Az Eur\u00f3pai\n Kardiol\u00f3gus T\u00e1rsas\u00e1g Cardiomyopathia Ir\u00e1nyelv\u00e9ben felt\u00fcntetett klinikai\n gyan\u00fajelek jelent\u0151s r\u00e9sze irodalmi adatok alapj\u00e1n alacsonyabb ell\u00e1t\u00e1si\n szinteken, illetve az alapell\u00e1t\u00e1sban is felismerhet\u0151, felgyors\u00edtva ezzel a\n diagnosztikus utat, ler\u00f6vid\u00edtve a progn\u00f3zism\u00f3dos\u00edt\u00f3 ter\u00e1pi\u00e1ig eltelt id\u0151t. A\n kivizsg\u00e1l\u00e1snak tartalmaznia kell az EKG, az alapvet\u0151 laborat\u00f3riumi param\u00e9terek\n \u00e9rt\u00e9kel\u00e9s\u00e9t, az extracardialis t\u00fcnetek keres\u00e9s\u00e9t, a megfelel\u0151 csal\u00e1di anamn\u00e9zis\n felv\u00e9tel\u00e9t, figyelembe v\u00e9ve a fenot\u00edpusos megjelen\u00e9st az \u00e9letkorral\n \u00f6sszef\u00fcgg\u00e9sben. Mindezek mellett kiemelend\u0151 a multimod\u00e1lis konvencion\u00e1lis \u00e9s\n emelt szint\u0171 k\u00e9palkot\u00e1s a betegs\u00e9g klinikai gyan\u00faja eset\u00e9n. Orv Hetil. 2026;\n 167(38): 1495\u20131506.<\/jats:p>","DOI":"10.1556\/650.2026.33616","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:54:52Z","timestamp":1789883692000},"page":"1495-1506","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["Diagnosztikus \u00e9bers\u00e9g \u00e9s a klinikai gyan\u00fajelek a hypertrophi\u00e1s cardiomyopathia napi gyakorlat\u00e1ban"],"prefix":"10.1556","volume":"167","author":[{"given":"Zsolt","family":"Forrai","sequence":"first","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"},{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Klinikai Orvostudom\u00e1nyi Doktori Iskola Szeged Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1l P\u00e9ter","family":"Sch\u00e4ffer","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s G.","family":"Gergely","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabet Mirjam","family":"Boldizs\u00e1r","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Andr\u00e9ka","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Pir\u00f3th","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-2820","authenticated-orcid":true,"given":"Fanni","family":"B\u00e1nfi-Bacs\u00e1rdi","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"},{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Klinikai Orvostudom\u00e1nyi Doktori Iskola Szeged Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Muk","sequence":"additional","affiliation":[{"name":"Gottsegen Gy\u00f6rgy Orsz\u00e1gos Kardiovaszkul\u00e1ris Int\u00e9zet, Feln\u0151tt Kardiol\u00f3giai Oszt\u00e1ly Budapest, Haller u. 29., 1096 Magyarorsz\u00e1g"},{"name":"Szegedi Tudom\u00e1nyegyetem, Szent-Gy\u00f6rgyi Albert Orvostudom\u00e1nyi Kar, Klinikai Orvostudom\u00e1nyi Doktori Iskola Szeged Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC guidelines for\n the management of cardiomyopathies. Eur Heart J. 2023; 44: 3503-3626.\n httppps:\/\/doi.org\/10.1093\/eurheartj\/ehad194"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic\n cardiomyopathy in a general population of young adults. Echocardiographic\n analysis of 4111 subjects in the CARDIA study. Coronary artery risk development\n in (young) adults. Circulation 1995; 92: 785-789.\n httppps:\/\/doi.org\/10.1161\/01.CIR.92.4.785","DOI":"10.1161\/01.CIR.92.4.785"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Maron BJ, Rowin EJ, Maron MS. Global burden of hypertrophic\n cardiomyopathy. JACC Heart Fail. 2018; 6: 376-378.\n httppps:\/\/doi.org\/10.1016\/j.jchf.2018.03.004","DOI":"10.1016\/j.jchf.2018.03.004"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Santner V, Granitz C, Gr\u00fcbler MR, et al. The prospective Austrian\n hypertrophic cardiomyopathy registry - design, methods and results of the run-in\n period. Heart Fail Rev. 2026; 31: 31-56.\n httppps:\/\/doi.org\/10.1007\/s10741-026-10630-6","DOI":"10.1007\/s10741-026-10630-6"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Niemiec M, Stec M, Grzybowski J, et al. What do we know about\n hypertrophic cardiomyopathy in Poland in the period 2016-2021 based on data from\n the public health system? Int J Public Health 2026; 71: 1608693.\n httppps:\/\/doi.org\/10.3389\/ijph.2026.1608693","DOI":"10.3389\/ijph.2026.1608693"},{"key":"R6","unstructured":"Silverdal J, Delavaran T, Smith JG, et al. Epidemiological trends in\n hypertrophic cardiomyopathy in adults - a Swedish nationwide registry study. Eur\n J Heart Fail. 2026; 4: 22 xuag132."},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Butzner M, Maron M, Sarocco P, et al. Clinical diagnosis of\n hypertrophic cardiomyopathy over time in the United States (a population-based\n claims analysis). Am J Cardiol. 2021; 159: 107-112.\n httppps:\/\/doi.org\/10.1016\/j.amjcard.2021.08.024","DOI":"10.1016\/j.amjcard.2021.08.024"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Canepa M, Olivotto I. Evolving epidemiology of hypertrophic\n cardiomyopathy: shifting the focus from instant to lifetime risk awareness. Circ\n Heart Fail. 2022; 15: e009873.\n httppps:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.122.009873","DOI":"10.1161\/CIRCHEARTFAILURE.122.009873"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Canepa M, Fumagalli C, Tini G, et al. Temporal trend of age at\n diagnosis in hypertrophic cardiomyopathy: an analysis of the International\n Sarcomeric Human Cardiomyopathy Registry. Circ Heart Fail. 2020; 13: e007230.\n httppps:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.007230","DOI":"10.1161\/CIRCHEARTFAILURE.120.007230"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Maron BJ, Rowin EJ, Casey SA, et al. Hypertrophic cardiomyopathy in\n adulthood associated with low cardiovascular mortality with contemporary\n management strategies. J Am Coll Cardiol. 2015; 65: 1915-1928.\n httppps:\/\/doi.org\/10.1016\/j.jacc.2015.02.061","DOI":"10.1016\/j.jacc.2015.02.061"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Maron BJ. Clinical course and management of hypertrophic\n cardiomyopathy. N Engl J Med. 2018; 379: 655-668.\n httppps:\/\/doi.org\/10.1056\/NEJMra1710575","DOI":"10.1056\/NEJMra1710575"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Butzner M, Aronitz E, Cameron H, et al. An evidence review and gap\n analysis for obstructive hypertrophic cardiomyopathy. BMC Cardiovasc Disord.\n 2024; 24: 416.\n httppps:\/\/doi.org\/10.1186\/s12872-024-04084-7","DOI":"10.1186\/s12872-024-04084-7"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Lorenzini M, Anastasiou Z, O\u2019Mahony C, et al. Mortality among\n referral patients with hypertrophic cardiomyopathy vs the general european\n population. JAMA Cardiol. 2020; 5: 73-80.\n httppps:\/\/doi.org\/10.1001\/jamacardio.2019.4534","DOI":"10.1001\/jamacardio.2019.4534"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Maron BJ, Rowin EJ, Casey SA, et al. How hypertrophic cardiomyopathy\n became a contemporary treatable genetic disease with low mortality: shaped by 50\n years of clinical research and practice. JAMA Cardiol. 2016; 1: 98-105.\n httppps:\/\/doi.org\/10.1001\/jamacardio.2015.0354","DOI":"10.1001\/jamacardio.2015.0354"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Abdelfattah OM, Martinez M, Sayed A, et al. Temporal and global\n trends of the incidence of sudden cardiac death in hypertrophic cardiomyopathy.\n JACC Clin Electrophysiol. 2022; 8: 1417-1427.\n httppps:\/\/doi.org\/10.1016\/j.jacep.2022.07.012","DOI":"10.1016\/j.jacep.2022.07.012"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Maron BJ, Ommen SR, Nishimura RA, et al. Evolution and\n transformation of hypertrophic cardiomyopathy from a high risk to a treatable\n low mortality disease with contemporary clinical research strategies. J Am Heart\n Assoc. 2026; 15: e047462.\n httppps:\/\/doi.org\/10.1161\/JAHA.125.047462","DOI":"10.1161\/JAHA.125.047462"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Maron MS, Rowin EJ, Maron BJ. The paradigm of sudden death\n prevention in hypertrophic cardiomyopathy. Am J Cardiol. 2024; 212S: S64-S76.\n httppps:\/\/doi.org\/10.1016\/j.amjcard.2023.10.076","DOI":"10.1016\/j.amjcard.2023.10.076"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Maron BJ, Rowin EJ, Maron MS. Advances in the management of\n hypertrophic cardiomyopathy leading to low disease-related mortality in 2023. Am\n J Cardiol. 2024; 212S: S77-S82.\n httppps:\/\/doi.org\/10.1016\/j.amjcard.2023.10.073","DOI":"10.1016\/j.amjcard.2023.10.073"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Panichella G, Capelli F, Pieroni M. et al. Florence\n cardiomyopathies. Eur Heart J. Valvular Structural Heart Dis. 2026; 2; xwag021.\n httppps:\/\/doi.org\/10.1093\/ehjvshd\/xwag021","DOI":"10.1093\/ehjvshd\/xwag021"},{"key":"R20","unstructured":"Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on\n diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the\n Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society\n of Cardiology (ESC). Eur Heart J. 2014; 35: 2733-2779.\n httppps:\/\/doi.org\/10.1093\/eurheartj\/ehu284"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Ommen SR, Ho CY, Asif IM, et al. 2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR\n guideline for the management of hypertrophic cardiomyopathy: a report of the\n American Heart Association\/American College of Cardiology Joint Committee on\n clinical practice guidelines. Circulation 2024; 149: e1239-e1311. Erratum:\n Circulation 2024; 150: e198.\n httppps:\/\/doi.org\/10.1161\/CIR.0000000000001277","DOI":"10.1161\/CIR.0000000000001277"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic work-up in\n cardiomyopathies: bridging the gap between clinical phenotypes and final\n diagnosis. A position statement from the ESC Working Group on Myocardial and\n Pericardial Diseases. Eur Heart J. 2013; 34: 1448-1458.\n httppps:\/\/doi.org\/10.1093\/eurheartj\/ehs397","DOI":"10.1093\/eurheartj\/ehs397"},{"key":"R23","unstructured":"Bonow RO, Mann DL, Tomaselli GF, et al. (eds.) Braunwald\u2019s heart\n disease. Elsevier, Amszterdam, 2025."},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Adabag AS, Kuskowski MA, Maron BJ. Determinants for clinical\n diagnosis of hypertrophic cardiomyopathy. Am J Cardiol. 2006; 98: 1507-1511.\n httppps:\/\/doi.org\/10.1016\/j.amjcard.2006.07.029","DOI":"10.1016\/j.amjcard.2006.07.029"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Lewontin M, Kaplan E, Bilchick KC, et al. Advanced diagnosis of\n hypertrophic cardiomyopathy with AI-ECG and differences based on ethnicity and\n HCM subtype. J Clin Med. 2025; 14: 4718.\n httppps:\/\/doi.org\/10.3390\/jcm14134718","DOI":"10.3390\/jcm14134718"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Sakhnini A, Montazeri M, Chow C, et al. Genotype and family history\n as risk markers of sudden cardiac death in hypertrophic cardiomyopathy. J Am\n Coll Cardiol EP. 2026; 12: 1247-1256.\n httppps:\/\/doi.org\/10.1016\/j.jacep.2026.01.033","DOI":"10.1016\/j.jacep.2026.01.033"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Roberts A, Allanson J, Jadico SK, et al. The cardiofaciocutaneous\n syndrome. J Med Genet. 2006; 43: 833-842.\n httppps:\/\/doi.org\/10.1136\/jmg.2006.042796","DOI":"10.1136\/jmg.2006.042796"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Stevenson DA, Yang FC. The musculoskeletal phenotype of the\n RASopathies. Am J Med Genet C Semin Med Genet. 2011; 157C: 90-103.\n httppps:\/\/doi.org\/10.1002\/ajmg.c.30296","DOI":"10.1002\/ajmg.c.30296"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Falk RH. Diagnosis and management of the cardiac amyloidoses.\n Circulation 2005; 112: 2047-2060.\n httppps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.489187","DOI":"10.1161\/CIRCULATIONAHA.104.489187"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Maurizi N, Rella V, Fumagalli C, et al. Prevalence of cardiac\n amyloidosis among adult patients referred to tertiary centres with an initial\n diagnosis of hypertrophic cardiomyopathy. Int J Cardiol. 2020; 300: 191-195.\n httppps:\/\/doi.org\/10.1016\/j.ijcard.2019.07.051","DOI":"10.1016\/j.ijcard.2019.07.051"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other\n lysosomal storage disorders. Heart 2007; 93: 528-535.\n httppps:\/\/doi.org\/10.1136\/hrt.2005.063818","DOI":"10.1136\/hrt.2005.063818"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Guler A, Gorgulu BK, Surgit O, et al. Prevalence and characteristics\n of normal electrocardiograms in hypertrophic cardiomyopathy. J Electrocardiol.\n 2026; 96: 154363.\n httppps:\/\/doi.org\/10.1016\/j.jelectrocard.2026.154363","DOI":"10.1016\/j.jelectrocard.2026.154363"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Biagini E, Pazzi C, Olivotto I, et al. Usefulness of\n electrocardiographic patterns at presentation to predict long-term risk of\n cardiac death in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2016;\n 118: 432-439.\n httppps:\/\/doi.org\/10.1016\/j.amjcard.2016.05.023","DOI":"10.1016\/j.amjcard.2016.05.023"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"McLeod CJ, Ackerman MJ, Nishimura RA, et al. Outcome of patients\n with hypertrophic cardiomyopathy and a normal electrocardiogram. J Am Coll\n Cardiol. 2009; 54: 229-233.\n httppps:\/\/doi.org\/10.1016\/j.jacc.2009.02.071","DOI":"10.1016\/j.jacc.2009.02.071"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Forrai Z, B\u00e1nfi-Bacs\u00e1rdi F, Pilecky D, et al. Prevalence of ECG\n abnormalities in hypertrophic cardiomyopathy: who seeks will find.\n [EKG-elt\u00e9r\u00e9sek gyakoris\u00e1ga hypertrophi\u00e1s cardiomyopathi\u00e1ban: aki keres, az\n tal\u00e1l.] Orv Hetil. 2025; 166: 970-981. [Hungarian]\n httppps:\/\/doi.org\/10.1556\/650.2025.33289","DOI":"10.1556\/650.2025.33289"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Bernardini A, Crotti L, Olivotto I, et al. Diagnostic and prognostic\n electrocardiographic features in patients with hypertrophic cardiomyopathy. Eur\n Heart J Suppl. 2023; 25(Suppl C): 173-C178. Erratum: Eur Heart J Suppl. 2023;\n 25(Suppl C): suad121. Erratum: Eur Heart J Suppl. 2023; 25(Suppl C): C178.\n httppps:\/\/doi.org\/10.1093\/eurheartjsupp\/suad074","DOI":"10.1093\/eurheartjsupp\/suad074"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Babur Guler G, Guler A, Surgit O, et al. Evaluation of artificial\n intelligence-based electrocardiogram analysis tools in patients with\n hypertrophic cardiomyopathy. Eur Heart J Digit Health 2026; 7: ztag026.\n httppps:\/\/doi.org\/10.1093\/ehjdh\/ztag026","DOI":"10.1093\/ehjdh\/ztag026"},{"key":"R38","unstructured":"Maurizi N, Monda E, Pieroni M, et al. Development of a\n smartphone-based app to support the differential diagnosis in patients with\n primary left ventricular hypertrophy. Eur Heart J Digit Health 2026; 7:\n ztaf105."},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Charron P, Arad M, Arbustini E, et al. Genetic counselling and\n testing in cardiomyopathies: a position statement of the European Society of\n Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J.\n 2010; 31: 2715-2726.\n httppps:\/\/doi.org\/10.1093\/eurheartj\/ehq271","DOI":"10.1093\/eurheartj\/ehq271"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Rani DS, Nallari P, Priyamvada S, et al. High prevalence of arginine\n to glutamine substitution at 98, 141 and 162 positions in troponin I (TNNI3)\n associated with hypertrophic cardiomyopathy among Indians. BMC Med Genet. 2012;\n 13: 69. httppps:\/\/doi.org\/10.1186\/1471-2350-13-69","DOI":"10.1186\/1471-2350-13-69"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Lorenzini M, Norrish G, Field E, et al. Penetrance of hypertrophic\n cardiomyopathy in sarcomere protein mutation carriers. J Am Coll Cardiol. 2020;\n 76: 550-559.\n httppps:\/\/doi.org\/10.1016\/j.jacc.2020.06.011","DOI":"10.1016\/j.jacc.2020.06.011"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Leigh JA, O\u2019Neal WT, Soliman EZ. Electrocardiographic left\n ventricular hypertrophy as a predictor of cardiovascular disease independent of\n left ventricular anatomy in subjects aged \u226565 years. Am J Cardiol. 2016; 117:\n 1831-1835.\n httppps:\/\/doi.org\/10.1016\/j.amjcard.2016.03.020","DOI":"10.1016\/j.amjcard.2016.03.020"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"Maurizi N, Monda E, Biagini E, et al. Hypertrophic cardiomyopathy:\n prevalence of disease-specific red flags. Eur Heart J. 2025; 46: 3082-3094.\n httppps:\/\/doi.org\/10.1093\/eurheartj\/ehaf026","DOI":"10.1093\/eurheartj\/ehaf026"},{"key":"R44","doi-asserted-by":"crossref","unstructured":"Vincze V, P\u00e1link\u00e1s ED, Zar\u00e1nd B, et al. Hypertrophic cardiomyopathy\n and pregnancy - gaining insight before labor and delivery. [A hipertr\u00f3fi\u00e1s\n cardiomyopathia \u00e9s a v\u00e1rand\u00f3ss\u00e1g - hogy ne csak a sz\u00fcl\u0151szob\u00e1n \u201cker\u00fclj\u00fcnk\n k\u00e9pbe\u201d.] Cardiol Hung. 2025; 55: 114-121. [Hungarian]\n httppps:\/\/doi.org\/10.26430\/CHUNGARICA.2025.55.2.114","DOI":"10.26430\/CHUNGARICA.2025.55.2.114"},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Teresi L, Trimarchi G, Licordari R, et al. Hypertrophic\n cardiomyopathy phenocopies: classification, key features, and differential\n diagnosis. Biomedicines 2025; 13: 3062.\n httppps:\/\/doi.org\/10.3390\/biomedicines13123062","DOI":"10.3390\/biomedicines13123062"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Cardim N, Haugaa K, Mohiddin SA, et al. Role of multi-modality\n cardiac imaging in the management of patients with hypertrophic cardiomyopathy\n in 2025. A clinical consensus statement of the European Association of\n Cardiovascular Imaging (EACVI) of the ESC. Eur Heart J Cardiovasc Imaging 2026;\n 27: 369-399. httppps:\/\/doi.org\/10.1093\/ehjci\/jeaf282","DOI":"10.1093\/ehjci\/jeaf282"},{"key":"R47","doi-asserted-by":"crossref","unstructured":"Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac\n chamber quantification by echocardiography in adults: an update from the\n American Society of Echocardiography and the European Association of\n Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015; 16: 233-270.\n Erratum: Eur Heart J Cardiovasc Imaging 2016; 17: 412. Erratum: Eur Heart J\n Cardiovasc Imaging 2016; 17: 969.\n httppps:\/\/doi.org\/10.1093\/ehjci\/jew041","DOI":"10.1093\/ehjci\/jew041"},{"key":"R48","doi-asserted-by":"crossref","unstructured":"Schirmer H, Lunde P, Rasmussen K. Prevalence of left ventricular\n hypertrophy in a general population. The Troms\u00f8 Study. Eur Heart J. 1999; 20:\n 429-438. httppps:\/\/doi.org\/10.1053\/euhj.1998.1314","DOI":"10.1053\/euhj.1998.1314"},{"key":"R49","doi-asserted-by":"crossref","unstructured":"Cardim N, Galderisi M, Edvardsen T, et al. Role of multimodality\n cardiac imaging in the management of patients with hypertrophic cardiomyopathy:\n an expert consensus of the European Association of Cardiovascular Imaging\n Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging 2015;\n 16: 280. httppps:\/\/doi.org\/10.1093\/ehjci\/jeu291","DOI":"10.1093\/ehjci\/jeu291"},{"key":"R50","doi-asserted-by":"crossref","unstructured":"Stankowski K, Celeste F, Muratori M, et al. Exploring morphologic\n and functional variants in hypertrophic cardiomyopathy: an echocardiographic and\n doppler review. Diagnostics (Basel) 2025; 15: 2688.\n httppps:\/\/doi.org\/10.3390\/diagnostics15212688","DOI":"10.3390\/diagnostics15212688"},{"key":"R51","unstructured":"Noureldin RA, Liu S, Nacif MS, et al. The diagnosis of hypertrophic\n cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson.\n 2012; 14: 17.\n httppps:\/\/doi.org\/10.1186\/1532-429X-14-17"},{"key":"R52","doi-asserted-by":"crossref","unstructured":"Gjesdal O, Bluemke DA, Lima JA. Cardiac remodeling at the population\n level risk factors, screening and outcomes. Nat Rev Cardiol. 2011; 8: 673-685.\n httppps:\/\/doi.org\/10.1038\/nrcardio.2011.154","DOI":"10.1038\/nrcardio.2011.154"},{"key":"R53","doi-asserted-by":"crossref","unstructured":"Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic\n cardiomyopathy is predominantly a disease of left ventricular outflow tract\n obstruction. Circulation 2006; 114: 2232-2239.\n httppps:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.644682","DOI":"10.1161\/CIRCULATIONAHA.106.644682"},{"key":"R54","doi-asserted-by":"crossref","unstructured":"Massera D, Long C, Xia Y, et al. Unmasking obstruction in\n hypertrophic cardiomyopathy with postprandial resting and treadmill stress\n echocardiography. J Am Soc Echocardiogr. 2024; 37: 971-980.\n httppps:\/\/doi.org\/10.1016\/j.echo.2024.06.011","DOI":"10.1016\/j.echo.2024.06.011"},{"key":"R55","doi-asserted-by":"crossref","unstructured":"Mande\u015f L, Ro\u015fca M, Ciuperc\u0103 D, et al. The role of echocardiography\n for diagnosis and prognostic stratification in hypertrophic cardiomyopathy. J\n Echocardiogr. 2020; 18: 137-148.\n httppps:\/\/doi.org\/10.1007\/s12574-020-00467-9","DOI":"10.1007\/s12574-020-00467-9"},{"key":"R56","doi-asserted-by":"crossref","unstructured":"O\u2019Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk\n prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM\n risk-SCD). Eur Heart J. 2014; 35: 2010-2020.\n httppps:\/\/doi.org\/10.1093\/eurheartj\/eht439","DOI":"10.1093\/eurheartj\/eht439"},{"key":"R57","doi-asserted-by":"crossref","unstructured":"Praz F, Borger MA, Lanz J, et al. 2025 ESC\/EACTS Guidelines for the\n management of valvular heart disease. Eur Heart J. 2025; 46: 4635-4736. Erratum:\n Eur Heart J. 2026 Aug 06: ehag625.\n httppps:\/\/doi.org\/10.1093\/ejcts\/ezaf393","DOI":"10.1093\/ejcts\/ezaf393"},{"key":"R58","doi-asserted-by":"crossref","unstructured":"Podlesnikar T, Cardim N, Ajmone Marsan N, et al. EACVI survey on\n hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022; 23: 590-597.\n httppps:\/\/doi.org\/10.1093\/ehjci\/jeab270","DOI":"10.1093\/ehjci\/jeab270"},{"key":"R59","doi-asserted-by":"crossref","unstructured":"Vidal-Perez R, Brand\u00e3o M, Zaher W, et al. Value of cardiac magnetic\n resonance on the risk stratification of cardiomyopathies. World J Cardiol. 2023;\n 15: 487-499.\n httppps:\/\/doi.org\/10.4330\/wjc.v15.i10.487","DOI":"10.4330\/wjc.v15.i10.487"},{"key":"R60","doi-asserted-by":"crossref","unstructured":"Rosmini S, Biagini E, O\u2019Mahony C, et al. Relationship between\n aetiology and left ventricular systolic dysfunction in hypertrophic\n cardiomyopathy. Heart 2017; 103: 300-306.\n httppps:\/\/doi.org\/10.1136\/heartjnl-2016-310138","DOI":"10.1136\/heartjnl-2016-310138"},{"key":"R61","doi-asserted-by":"crossref","unstructured":"Pozsonyi Z, Pesko G, Takacs H, et al. Variant transthyretin\n amyloidosis (ATTRv) in Hungary: first data on epidemiology and clinical\n features. Genes (Basel) 2021; 12: 1152.\n httppps:\/\/doi.org\/10.3390\/genes12081152","DOI":"10.3390\/genes12081152"},{"key":"R62","doi-asserted-by":"crossref","unstructured":"Pozsonyi Z. Specific therapeutic options for transthyretin\n amyloidosis. Cardiol Hung. 2024; 54: 491-496.\n httppps:\/\/doi.org\/10.26430\/CHUNGARICA.2024.54.6.491","DOI":"10.26430\/CHUNGARICA.2024.54.6.491"},{"key":"R63","doi-asserted-by":"crossref","unstructured":"Palinkas ED, Sepp R, Olivotto I. A new chapter in the management of\n hypertrophic cardiomyopathy: cardiac myosin inhibitors. Cardiol Hung. 2023; 53:\n 337-342.\n httppps:\/\/doi.org\/10.26430\/CHUNGARICA.2023.53.4.337","DOI":"10.26430\/CHUNGARICA.2023.53.4.337"},{"key":"R64","doi-asserted-by":"crossref","unstructured":"Nagy V, R\u00e1cz G, Tak\u00e1cs H, et al. Mavacamten effectively reduces\n >100 mmHg left ventricular outflow tract gradients as early as one week of\n treatment in obstructive hypertrophic cardiomyopathy. Int J Cardiol. 2026; 442:\n 133882.\n httppps:\/\/doi.org\/10.1016\/j.ijcard.2025.133882","DOI":"10.1016\/j.ijcard.2025.133882"},{"key":"R65","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the\n diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;\n 42: 3599-3726. Erratum: Eur Heart J. 2021; 42: 4901.","DOI":"10.1093\/eurheartj\/ehab670"},{"key":"R66","doi-asserted-by":"crossref","unstructured":"Forrai Zs, Sch\u00e4ffer PP, Gergely TG, et al. Determination of\n albuminuria in the light of the first-line pharmacotherapy of heart failure with\n reduced ejection fraction. [Az albuminuria vizsg\u00e1lata a cs\u00f6kkent ejekci\u00f3s\n frakci\u00f3j\u00fa sz\u00edvel\u00e9gtelens\u00e9g els\u0151 vonalbeli gy\u00f3gyszeres ter\u00e1pi\u00e1j\u00e1nak t\u00fckr\u00e9ben.]\n Orv Hetil. 2026; 167: 383-395. [Hungarian]\n httppps:\/\/doi.org\/10.1556\/650.2026.33492","DOI":"10.1556\/650.2026.33492"},{"key":"R67","unstructured":"P\u00e1link\u00e1s ED, Nagy V, Varga A, et al. Evaluation of of latent left\n ventricular outflow tract obstruction in patient with hypertrophic\n cardiomyopathy by bicycle stress echocardiography. [A l\u00e1tens bal kamra\n ki\u00e1raml\u00e1si p\u00e1lya obstrukci\u00f3 vizsg\u00e1lata ker\u00e9kp\u00e1ros stressz echokardiogr\u00e1fi\u00e1val\n hypertrophi\u00e1s cardiomyopathi\u00e1s betegekben.] Med Thorac. 2019; 72: 3-11.\n [Hungarian]"},{"key":"R68","doi-asserted-by":"crossref","unstructured":"P\u00e1link\u00e1s ED, Ciampi Q, Picano E. The expanding role of stress\n echocardiography in hypertrophic cardiomyopathy. Cardiol Hung. 2019; 49:\n 330-337.\n httppps:\/\/doi.org\/10.26430\/CHUNGARICA.2019.49.5.330","DOI":"10.26430\/CHUNGARICA.2019.49.5.330"},{"key":"R69","doi-asserted-by":"crossref","unstructured":"Nagy V, R\u00e1cz G, Boda K, et al. Characterisation of interrelations\n among myocardial work parameters in patients with hypertrophic cardiomyopathy:\n differences between non-obstructive and obstructive disease. Front Cardiovasc\n Med. 2026; 12: 1670503.\n httppps:\/\/doi.org\/10.3389\/fcvm.2025.1670503","DOI":"10.3389\/fcvm.2025.1670503"},{"key":"R70","doi-asserted-by":"crossref","unstructured":"Nemes A, Korm\u00e1nyos \u00c1. Echocardiographic evaluation of the left\n ventricular global myocardial work. [A bal kamrai glob\u00e1lis myocardialis munka\n echokardiogr\u00e1fi\u00e1s vizsg\u00e1lata.] Orv Hetil. 2022; 163: 495-499. [Hungarian]\n httppps:\/\/doi.org\/10.1556\/650.2022.32400","DOI":"10.1556\/650.2022.32400"},{"key":"R71","doi-asserted-by":"crossref","unstructured":"Trimarchi G, Carerj S, Di Bella G, et al. Clinical applications of\n myocardial work in echocardiography: a comprehensive review. J Cardiovasc\n Echogr. 2024; 34: 99-113.\n httppps:\/\/doi.org\/10.4103\/jcecho.jcecho_37_24","DOI":"10.4103\/jcecho.jcecho_37_24"},{"key":"R72","doi-asserted-by":"crossref","unstructured":"Rudolph A, Abdel-Aty H, Bohl S, et al. Noninvasive detection of\n fibrosis applying contrast-enhanced cardiac magnetic resonance in different\n forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol.\n 2009; 53: 284-291.\n httppps:\/\/doi.org\/10.1016\/j.jacc.2008.08.064","DOI":"10.1016\/j.jacc.2008.08.064"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/38\/article-p1495.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/38\/article-p1495.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/38\/article-p1495.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:55:38Z","timestamp":1789883738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/38\/article-p1495.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":72,"journal-issue":{"issue":"38"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33616","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]}}}